Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14895736 | 0.96 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2ATMLMNAKMT2A | |
| SCHEMBL6492889 | 0.73 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2ATMLMNAKMT2A | |
| SCHEMBL4155861 | 0.67 | GRM2 (0.58) | SMN1; SMN2LMNAMAPT | |
| SCHEMBL30792923 | 0.67 | HSD11B1 (0.52) | SMN1; SMN2ATMKMT2ANPC1RAB9A | |
| SCHEMBL17995255 | 0.67 | HSD11B1 (0.52) | SMN1; SMN2ATMKMT2ANPC1RAB9A | |
| SCHEMBL15136392 | 0.67 | RAB9A (0.44) | ALDH1A1SMN1; SMN2ATMKMT2ATSHR | |
| SCHEMBL1997873 | 0.66 | PSMB8 (0.56) | ALDH1A1SMN1; SMN2ATMLMNAKMT2A | |
| SCHEMBL15154856 | 0.66 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2ATMLMNAKMT2A | |
| SCHEMBL30421147 | 0.65 | OPRM1 (0.47) | ALDH1A1SMN1; SMN2ATMLMNATSHR | |
| SCHEMBL19093956 | 0.65 | OPRM1 (0.47) | ALDH1A1SMN1; SMN2ATMLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | ALDH1A1 3777/4885SMN1; SMN2 1091/4885PDE4A 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.